Adjuvant Trastuzumab: Does Time Really Matter?

Abstract

Trastuzumab is now the standard of care for metastatic and early breast cancer; however, questions remain regarding the optimal schedule of trastuzumab in the adjuvant setting. This commentary discusses the results from recent clinical trials with regard to the optimal duration of trastuzumab treatment, as well as the benefits of providing trastuzumab sequentially versus concurrently to chemotherapy.